van Kesteren R G, Duursma S A, Visser W J, van der Sluys Veer J, Backer Dirks O
Metab Bone Dis Relat Res. 1982;4(1):31-7. doi: 10.1016/0221-8747(82)90006-6.
Thirteen patients with primary osteoporosis were treated for two years with sodium fluoride (NaF), calcium and dihydrotachysterol (group A). The dose of NaF was modified according to the serum fluoride concentration, which was kept as constant as possible between 0.20 and 0.25 microgram/ml. In patients with bone fluoride content greater than or equal to 0.20% a significant increase in the volumetric density and in the surface percentage covered with osteoid and with osteoblasts was observed. A second group of 7 patients with primary osteoporosis was also treated for 2 years with calcium and dihydrotachysterol, but without fluoride (group B). In these patients no significant change in the volumetric density or in the surface percentage covered with osteoid or osteoblasts was found. Patients in group A with a bone fluoride content less than 0.20% could not be distinguished from the patients in group B. Based on the available data an advice was given for the dosage of NaF in patients with osteoporosis. Regular assessment of the serum fluoride concentration remains advisable.
13名原发性骨质疏松症患者接受了为期两年的氟化钠（NaF）、钙和二氢速甾醇治疗（A组）。根据血清氟浓度调整NaF剂量，尽可能将其保持在0.20至0.25微克/毫升之间。骨氟含量大于或等于0.20%的患者，其体积密度以及类骨质和覆盖有成骨细胞的表面百分比显著增加。另一组7名原发性骨质疏松症患者也接受了为期两年的钙和二氢速甾醇治疗，但未使用氟化物（B组）。这些患者的体积密度或类骨质或成骨细胞覆盖的表面百分比均未发现显著变化。A组中骨氟含量低于0.20%的患者与B组患者无法区分。根据现有数据，给出了骨质疏松症患者NaF的用药建议。定期评估血清氟浓度仍然是可取的。
